tbuckley/cabot-search huggingface dataset:
Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study
Authors: Kristine A. Frerichs, Monique C. Minnema, Mark-David Levin, Annemiek Broyl, Gerard Bos, Marie José Kersten, Tuna Mutis, Christie P.M. Verkleij, Patricia W.C. Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W. C. J. Van De Donk
Journal: Blood (2019)
Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis
Authors: Rebeca Bailén, Mi Kwon, Maria Jesus Pascual-Cascon, Anna Torrent, Christelle M Ferra, Jaime Sanz, Alberto Doblas-Marquez, Olga Benítez, Jose Luis Piñana Sanchez, Gillen Oarbeascoa, Nieves Dorado, Muñoz Cristina, Carolina Martínez-Laperche, Javier Anguita, Ismael Buño, José Luis Díez-Martín
Journal: Blood (2019)
Predictors of Progression in Patients With Stage B Aortic Regurgitation
Authors: Li-Tan Yang, Maurice Enriquez-Sarano, Hector I. Michelena, Vuyisile T. Nkomo, Christopher G. Scott, Kent R. Bailey, Didem Oguz, Muhammad Wajih Ullah, Patricia A. Pellikka
Journal: Journal of the American College of Cardiology (2019)
Functional Calcitriol/Vitamin D Receptor Signaling in Chronic Lymphocytic Leukemia
Authors: Marina Gerousi, Fotis Psomopoulos, Kostantia Kotta, Niki Stavroyianni, Achilles Anagnostopoulos, Ioannis Kotsianidis, Stavroula Ntoufa, Kostas Stamatopoulos
Journal: Blood (2019)
Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Phase I/II Study
Authors: Divaya Bhutani, Siyang Leng, Samuel Pan, Amer Assal, Alexander Wei, Julia Gould, Markus Y. Mapara, Suzanne Lentzsch
Journal: Blood (2019)
Pre-Clinical Activity of a Novel FcγRIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia.
Authors: Julie M. Roda, Rosa Lapalombella, Robert Baiocchi, Eugene Zhukocsky, John Desjarlais, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2007)
Role of HDAC8 Upregulation in Resistance of FLT3-ITD AML Stem Cells to FLT3 Inhibitors
Authors: Jun Long, Mingyuan Jia, Weiyue Fang, Xinjie Chen, Zhongyu Wang, Lili Mu, Rufang Xiang, Jun-Min LI, Dengli Hong, Aibin Liang, Jiong Hu
Journal: Blood (2019)
Nitric oxide modulates cardiomyocyte pH control through a biphasic effect on sodium/hydrogen exchanger-1
Authors: Mark A Richards, Jillian N Simon, Ruichong Ma, Aminah A Loonat, Mark J Crabtree, David J Paterson, Richard P Fahlman, Barbara Casadei, Larry Fliegel, Pawel Swietach
Journal: Cardiovascular Research (2019)

When activated, Na+/H+ exchanger-1 (NHE1) produces some of the largest ionic fluxes in the heart. NHE1-dependent H+ extrusion and Na+ entry strongly modulate cardiac physiology through the direct effects of pH on proteins and by influencing intracellular Ca2+ handling. To attain an appropriate level of activation, cardiac NHE1 must respond to myocyte-derived cues. Among physiologically important cues is nitric oxide (NO), which regulates a myriad of cardiac functions, but its actions on NHE1 are unclear.NHE1 activity was measured using pH-sensitive cSNARF1 fluorescence after acid-loading adult ventricular myocytes by an ammonium prepulse solution manoeuvre. NO signalling was manipulated by knockout of its major constitutive synthase nNOS, adenoviral nNOS gene delivery, nNOS inhibition, and application of NO-donors. NHE1 flux was found to be activated by low [NO], but inhibited at high [NO]. These responses involved cGMP-dependent signalling, rather than S-nitros(yl)ation. Stronger cGMP signals, that can inhibit phosphodiesterase enzymes, allowed [cAMP] to rise, as demonstrated by a FRET-based sensor. Inferring from the actions of membrane-permeant analogues, cGMP was determined to activate NHE1, whereas cAMP was inhibitory, which explains the biphasic regulation by NO. Activation of NHE1-dependent Na+ influx by low [NO] also increased the frequency of spontaneous Ca2+ waves, whereas high [NO] suppressed these aberrant forms of Ca2+ signalling.Physiological levels of NO stimulation increase NHE1 activity, which boosts pH control during acid-disturbances and results in Na+-driven cellular Ca2+ loading. These responses are positively inotropic but also increase the likelihood of aberrant Ca2+ signals, and hence arrhythmia. Stronger NO signals inhibit NHE1, leading to a reversal of the aforementioned effects, ostensibly as a potential cardioprotective intervention to curtail NHE1 overdrive.
STEM-24. THERAPEUTIC APPROACH OF STEM CELL CARRYING RETROVIRAL REPLICATING VECTORS IN HUMAN GLIOMA MODEL
Authors: Akihito Inagaki, Masamichi Takahashi, Shuichi Kamijima, Kei Hiraoka, Quincy Tam, Emmanuelle Faure-Kumar, Janet Treger, Brooke Bogan, Katrin Hacke, Sara Collins, Douglas Jolly, Noriyuki Kasahara
Journal: Neuro-Oncology (2019)

Abstract Toca 511, an improved retroviral replicating vectors (RRVs) expressing a codon-optimized cytosine deaminase, has shown highly promising evidence of therapeutic benefit in preclinical and clinical studies for gene therapy of glioma. In the present study, we engineered human mesenchymal stem cells (MSC) as tumor-homing cellular carriers that produce and release RRV, and evaluated the effect of this mode of virus delivery on the time course of intratumoral RRV dissemination. Human MSC isolates were engineered to produce RRV (MSC-RRV). Cytotoxicity assays confirmed efficient prodrug activator function in U-87 glioma cells transduced with vectors produced from MSC-RRV. To evaluate intratumoral migration activity and tumor-homing migration activity in vivo, individual MSC isolates were injected either directly into human glioma xenografts, or into the contralateral brain hemisphere. MSC-RRV isolates showing the highest levels of intratumoral migration activity were selected, and the efficiency of intratumoral dissemination and tumoricidal activity achieved by these isolates was compared against injection of RRV virus preparations in subcutaneous glioma models. Compared to virus injection, MSC-RRV achieved 1.6x-higher levels of tumor transduction (p&lt; 0.05), and 2x-reduced tumor growth (p=0.018) at earlier time points. In short-term survival studies using lower doses of MSC-RRV cells vs. RRV virus injected 14 days post-establishment of intracranial U-87 gliomas, a small but statistically significant prolongation of median survival was seen with intracranial tumors treated with MSC-RRV as compared to RRV (26 vs. 20 days, p&lt; 0.05) after only a single cycle of 5-FC prodrug. Thus, MSC can be employed as mobile tumor-homing RRV-producer cells, which release RRV as they migrate to tumor foci in vivo and actively penetrate into individual tumor masses, resulting in more rapid tumor transduction and earlier therapeutic efficacy, which may be advantageous particularly for multi-focal and metastatic disease. This study was funded by the California Institute for Regenerative Medicine (TR2-01791).
Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
Authors: Aaron D Goldberg, Catherine C. Coombs, Eunice S. Wang, Roland B. Walter, Chatchada Karanes, Carlos Enrique Vigil, Boo Messahel, Richard M. Stone, Robert H. Collins
Journal: Blood (2019)
Factors Associated With Measles Transmission in the United States During the Postelimination Era
Authors: Paul A. Gastañaduy, Sebastian Funk, Benjamin A. Lopman, Paul A. Rota, Manoj Gambhir, Bryan Grenfell, Prabasaj Paul
Journal: JAMA Pediatrics (2019)

<h3>Importance</h3> Measles cases and outbreaks continue to occur in the United States after the introduction of measles from endemic settings. <h3>Objective</h3> To discern the factors associated with measles transmission in the United States after measles had been eliminated. <h3>Design, Setting, and Participants</h3> This cross-sectional study was conducted from January 1, 2001, to December 31, 2017, in the United States among US residents and international visitors with confirmed measles. A maximum likelihood algorithm that uses the observed dates of rash onset and the known distribution of the serial interval (time between symptom onset in related consecutive cases) was applied to outbreak notification data to estimate the effective reproduction number (<i>R</i>), or the mean number of new infections generated per case. Transmissibility was assessed by comparing<i>R</i>based on the characteristics of primary and secondary cases of measles. <h3>Exposures</h3> Measles virus. <h3>Main Outcomes and Measures</h3> Effective reproduction number (<i>R</i>), or the mean number of successful transmission events per case of measles (ie, the mean number of persons to whom each patient with measles spreads measles). <h3>Results</h3> A total of 2218 individuals with confirmed measles cases (1025 female, 1176 male, and 17 sex not reported; median age, 15 years [range, 0-89 years]) reported from 2001 to 2017 were evaluated. Among patients who received no doses of measles vaccine,<i>R</i>was 0.76 (95% CI, 0.71-0.81); among patients who received 1 dose of measles vaccine,<i>R</i>was 0.17 (95% CI, 0.11-0.26); among patients who received 2 doses or more of measles vaccine,<i>R</i>was 0.27 (95% CI, 0.17-0.39); and among patients with unknown vaccination status,<i>R</i>was 0.52 (95% CI, 0.44-0.60). Among patients born before 1957,<i>R</i>was 0.35 (95% CI, 0.20-0.58), and among those born on or after 1957,<i>R</i>was 0.64 (95% CI, 0.61-0.68).<i>R</i>was higher when primary and secondary cases of measles were patients aged 5 to 17 years (0.36 [95% CI, 0.31-0.42]) compared with assortative transmission in other age groups (&lt;1 year, 0.14 [95% CI, 0.10-0.20]; 1-4 years, 0.25 [95% CI, 0.20-0.30]; 18-29 years, 0.19 [95% CI, 0.15-0.24]; 30-49 years, 0.15 [95% CI, 0.11-0.20]; ≥50 years, 0.04 [95% CI, 0.01-0.10]). <h3>Conclusions and Relevance</h3> The findings of this study support having high targets for 2-dose measles vaccine coverage, particularly among school-aged children in the United States.
Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia
Authors: Friedrich Stoelzel, Sarah Elizabeth Fordham, Wei Yu Lin, Helen Blair, Leo Ruhnke, Desireé Kunadt, Brigitte Mohr, Claire Elstob, Daniel Allsop, Devi Nandana, Emmanouela-Niki Soura, Catherine Park, Mohd Fadly, Thahira Rahman, Olaf Heidenreich, Heidi Altmann, Gail Jones, Tobias Menne, Manja Wobus, Graham Jackson, Helen Marr, Kenan Onel, Manja Meggendorfer, Torsten Haferlach, Martin Bornhäuser, James M. Allan
Journal: Blood (2019)
High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore
Authors: Yin Jie Koh, Michelle Poon, Yeh Ching Linn, William YK Hwang, Elson Neo, Aloysius YL Ho, Lip Kun Tan, Liang Piu Koh
Journal: Blood (2019)
SCIDOT-32. NEUROSURGICAL DELIVERY OF THE POLY ADP RIBOSE POLYMERASE-1 INHIBITOR OLAPARIB FROM A THERMO-RESPONSIVE BIODEGRADABLE PASTE POTENTIATES RADIOTHERAPY AND PROLONGS SURVIVAL IN HIGH-GRADE GLIOMA
Authors: Stuart Smith, Riccardo Serra, Jonathan Rowlinson, Noah Gorelick, Gareth Veal, Kevin Shakesheff, Henry Brem, Richard Grundy, Betty Tyler, Ruman Rahman
Journal: Neuro-Oncology (2019)

Abstract There has been considerable interest in repurposing the poly ADP ribose polymerase inhibitor and purported radiosensitiser olaparib (Lynparza), with a recent dose escalation study of olaparib plus temozolomide in recurrent GBM showing good tolerance (Fulton et al 2018). Due to systemic therapy-associated caveats such as dose-limiting toxicities and blood-brain-barrier penetration, here we assess localised post-surgical delivery of olaparib from our previously developed poly(DL-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) (PLGA/PEG) thermo-sensitive biodegradable paste. Metabolic and clonogenic assays revealed impaired proliferation and clonal growth respectively, upon acute exposure of high-grade glioma cells to olaparib (3–5µM), an effect dramatically potentiated with 3Gy radiation. Flow cytometry of Annexin V+/Propidium iodide+ rodent and human high-grade glioma cells, revealed a significant cell proportion increase at late stage apoptosis when exposed to 2–3µM olaparib and 3Gy radiation (relative to untreated, olaparib alone or radiation alone). A high-grade glioma orthotopic allograft study is ongoing where we already observe a significant overall survival benefit of locally-delivered 10% and 20% w/w (drug:polymer ratio) olaparib via PLGA/PEG paste post-surgery with adjuvant radiotherapy, compared to surgery/oral temozolomide/radiotherapy (GBM standard-of-care) and surgery/systemic olaparib (120 days vs. 44 vs 30 respectively). A more pronounced survival benefit, as determined by the total number of long-term surviving animals, was observed with combined PLGA/PEG/olaparib/temozolomide/radiotherapy or PLGA/PEG/olaparib/etoposide/radiotherapy. RNAseq data from 10 GBM patients show significantly elevated levels of apoptosis-inducing factor-1 in 5-aminolevulinic acid (5ALA)+ fluorescence–activated cell sorted populations (i.e. purified tumour cells from the invasive margin), relative to 5ALA- cells, confirming PARP-1 activity in infiltrative tumour cells. Collectively our data supports a clinical rationale for localised olaparib delivery with adjuvant radiotherapy.
BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma
Authors: Changying Jiang, Yang Liu, Joseph Mitchell McIntosh, Angela Leeming, Rongjia Zhang, William Lee, Krystle Nomie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael L. Wang
Journal: Blood (2019)
Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect® CLL Registry
Authors: Jeff P. Sharman, Anthony Mato, Neil E. Kay, Thomas J. Kipps, Nicole Lamanna, Mark Weiss, Chadi Nabhan, Ian Flinn, David L. Grinblatt, Mark F. Kozloff, Charles M. Farber, Kirsten Sullivan, Thomas Street, Arlene S. Swern, Christopher R. Flowers
Journal: Blood (2014)
AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?
Authors: Kelda Gardner, Mary-Elizabeth M. Percival, Paul C. Hendrie, Anna B. Halpern, Carole M. Shaw, Jacob Appelbaum, Bart L. Scott, Vivian G. Oehler, Roland B. Walter, Pamela S. Becker, Elihu H. Estey
Journal: Blood (2019)
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States
Authors: François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh
Journal: Blood (2019)
Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
Authors: Jakub Svoboda, Hatcher J. Ballard, Elise A. Chong, Meredith I LaRose, Steven M. Bair, Esin C. Namoglu, Mitchell E. Hughes, Sunita Dwivedy Nasta, Daniel J. Landsburg, Stefan K. Barta, James N. Gerson, Elizabeth Weber, Chase Walling, Marco Ruella, Noelle V. Frey, David L. Porter, Stephen J. Schuster
Journal: Blood (2019)
Heterogeneity in enterotoxigenic Escherichia coli and shigella infections in children under 5 years of age from 11 African countries: a subnational approach quantifying risk, mortality, morbidity, and stunting
Authors: Karoun H Bagamian, John D Anderson, Farzana Muhib, Oliver Cumming, Lindsey A Laytner, Thomas F Wierzba, Richard Rheingans
Journal: The Lancet Global Health (2019)

BackgroundDiarrhoea, a global cause of child mortality and morbidity, is linked to adverse consequences including childhood stunting and death from other diseases. Few studies explore how diarrhoeal mortality varies subnationally, especially by cause, which is important for targeting investments. Even fewer examine indirect effects of diarrhoeal morbidity on child mortality. We estimated the subnational distribution of mortality, morbidity, and childhood stunting attributable to enterotoxigenic Escherichia coli (ETEC) and shigella infection in children younger than 5 years from 11 eastern and central African countries. These pathogens are leading causes of diarrhoea in young children and have been linked to increased childhood stunting.MethodsWe combined proxy indicators of morbidity and mortality risk from the most recent Demographic and Health Surveys with published relative risks to estimate the potential distribution of diarrhoeal disease risk. To estimate subnational burden, we used country-specific or WHO region-specific morbidity and mortality estimates and distributed them subnationally by three indices that integrate relevant individual characteristics (ie, underweight, probability of receiving oral rehydration treatment of diarrhoea, and receiving vitamin A supplementation) and household characteristics (ie, type of drinking water and sanitation facilities).FindingsCharacterising ETEC and shigella subnational estimates of indirect morbidity (infection-attributable stunting) and indirect mortality (stunting-related deaths from other infectious diseases) identified high-risk areas that could be missed by traditional metrics. Burundi and Democratic Republic of the Congo had the highest ETEC-associated and shigella-associated mortality and stunting rates. Mozambique, Democratic Republic of the Congo, and Zimbabwe had the greatest subnational heterogeneity in most ETEC and shigella mortality measures. Inclusion of indirect ETEC and shigella mortality in burden estimates resulted in a 20–30% increase in total ETEC and shigella mortality rates in some subnational areas.InterpretationUnderstanding the indirect mortality and morbidity of diarrhoeal pathogens on a subnational level will strengthen disease control strategies and could have important implications for the relative impact and cost-effectiveness of new enteric vaccines. Because our methods rely on publicly available data, they could be employed for national planning.FundingBill & Melinda Gates Foundation.
RARE-35. MRI FINDINGS AT PROGRESSION IN ADULT PATIENTS WITH MEDULLOBLASTOMA
Authors: Christine Cordova, Elizabeth Vera, Orwa Aboud, Ramya Antony, Lisa Boris, Christine Bryla, Eric Burton, Sonja Crandon, Nicole Leggiero, Jennifer Reyes, Christine Siegel, Brett Theeler, Yamini Vyas, Kathleen Wall, Jing Wu, Mark Gilbert, Terri Armstrong, Marta Penas-Prado
Journal: Neuro-Oncology (2019)

Abstract Progression (PD) in medulloblastoma (MB) represents a diagnostic challenge due to imaging heterogeneity among/within patients. SHH (Sonic hedgehog)-MB is thought to recur mostly within the tumor bed (TB). In children, DWI restriction (DWIr) is more sensitive than contrast enhancement(CE) for first PD. Whether this is applicable to adults is unknown. METHODS Retrospective review of adults (age ≥18) with MB enrolled to Natural History study at NCI-NOB. Descriptive statistics of imaging at diagnosis and PD(CE, T2/FLAIR signal without CE, DWIr) and imaging patterns for each PD. RESULTS:14 adults with MB: 5 diagnosed in childhood (8–16 yrs), 9 as adults (18–45 yrs); Subtypes: 7 SHH, 3 non-WNT/non-SHH, 4 unknown. Eleven experienced ≥1 PD (6/7 SHH, 2/3 non-WNT/non-SHH, 3/4 unknown); median PD of 5 (range 1–9). Median age at first PD 31 years (range 10–46) with 5 first PDs &gt;5 years after diagnosis. In 10 patients with available baseline MRI, 9 had CE, and 8 DWIr (2 without DWI sequences). Of 48 total PDs, the commonest patterns were: brain LMD alone (n=14), TB alone or distant brain parenchyma alone (each n=7), distant brain parenchyma with brain LMD (n=6), and TB with either distant brain parenchyma or LMD (n=3). Of the 82 PD lesions, 23% (n=14) of brain lesions lacked DWIr, and 37% (n=23) had T2/FLAIR signal without CE. PD tissue confirmation obtained at 18 time points:16 cases with confirmed recurrence had heterogeneous characteristics; in 12 with brain PD: CE in 5, T2/FLAIR without CE in 3 (unknown: 4). 2 CE lesions revealed meningioma (one- atypical meningioma- had DWIr). CONCLUSIONS Imaging findings in adult patients with MB are highly heterogeneous. Despite high specificity of DWIr for PD in children, it failed for 23% of brain lesions across multiple patients. Most SHH-MB had PD outside the TB, unlike what is widely accepted in the literature.
A Novel Class of Bifunctional Immunotherapeutic That Exploit a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cells Expressing CD38 Demonstrates Anti-Multiple Myeloma Activity in Vitro and Ex Vivo against Patient Tumor Cells
Authors: Ann Marie Rossi, Anna Bunin, Lawrence Iben, Matthew Welsch, Tanya Berbasova, Caterina Riillo, Marco Rossi, Masaki Ohuchi, Enrique Alvarez, Naoko Kawakami, Takayuki Nagasawa, Pierfrancesco Tassone, David Spiegel, Luca Rastelli
Journal: Blood (2019)
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL
Authors: Michael Y. Choi, Emanuela M. Ghia, Tanya Siddiqi, William G. Wierda, Hun Ju Lee, Jacqueline C. Barrientos, Nicole Lamanna, Alec Goldenberg, Dimitrios Tzachanis, Erin G. Reid, Elizabeth K Weihe, Laura Z. Rassenti, Iris Isufi, Stewart Bieler, Xen Ianopulos, James B. Breitmeyer, Catriona Jamieson, Thomas J. Kipps
Journal: Blood (2019)
Defining Equity in Eligibility for Cancer Screening
Authors: Hilary A. Robbins, Mattias Johansson
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study
Authors: Shayna Sarosiek, John Mark Sloan, Karen Quillen, Dina Brauneis, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala
Journal: Blood (2019)
Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients
Authors: Rory McCulloch, Simon Rule, Toby A. Eyre, Harshita Goradia, Simon Bolam, Thomas Creasey, David Tucker, Michelle Furtado, Oliver Miles, Samuel Harrison, Amir Shenouda, Andrew Robinson, Matthew Wilson, Annabel McMillan, Nimish Shah, Graham McIlroy, David Dutton, Adam Bond, Luke Attwell, Alexander Langridge, Helen Parry, John Willan, Gavin Campbell, Deborah Turner, David Lewis, Helen McCarthy, Jonathan Lambert, Pamela McKay, Neil Phillips, Shankara Paneesha, Wendy Osborne, Mark Bishton, Nicola Crosbie
Journal: Blood (2019)